Is Neurosense Therapeutics Stock a Good Investment?
Neurosense Therapeutics Investment Advice | NRSN |
- Examine Neurosense Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neurosense Therapeutics' leadership team and their track record. Good management can help Neurosense Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Neurosense Therapeutics' business and its evolving consumer preferences.
- Compare Neurosense Therapeutics' performance and market position to its competitors. Analyze how Neurosense Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Neurosense Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neurosense Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neurosense Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neurosense Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Neurosense Therapeutics Stock
Researching Neurosense Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 31.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.76. Neurosense Therapeutics had not issued any dividends in recent years.
To determine if Neurosense Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neurosense Therapeutics' research are outlined below:
| Neurosense Therapeutics had very high historical volatility over the last 90 days | |
| Neurosense Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Neurosense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company outstanding shares are owned by corporate insiders |
Neurosense Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neurosense Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neurosense Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Neurosense Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.39 M.Basic technical analysis of Neurosense Stock
As of the 5th of March, Neurosense Therapeutics secures the Mean Deviation of 3.29, risk adjusted performance of 0.0336, and Downside Deviation of 4.15. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurosense Therapeutics, as well as the relationship between them.Neurosense Therapeutics' Outstanding Corporate Bonds
Neurosense Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neurosense Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neurosense bonds can be classified according to their maturity, which is the date when Neurosense Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Neurosense Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neurosense Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0336 | |||
| Market Risk Adjusted Performance | (0.32) | |||
| Mean Deviation | 3.29 | |||
| Semi Deviation | 3.63 | |||
| Downside Deviation | 4.15 | |||
| Coefficient Of Variation | 3055.4 | |||
| Standard Deviation | 5.05 | |||
| Variance | 25.48 | |||
| Information Ratio | 0.0482 | |||
| Jensen Alpha | 0.1137 | |||
| Total Risk Alpha | 0.7345 | |||
| Sortino Ratio | 0.0587 | |||
| Treynor Ratio | (0.33) | |||
| Maximum Drawdown | 31.95 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 6.31 | |||
| Downside Variance | 17.19 | |||
| Semi Variance | 13.2 | |||
| Expected Short fall | (4.46) | |||
| Skewness | 1.78 | |||
| Kurtosis | 7.72 |
| Risk Adjusted Performance | 0.0336 | |||
| Market Risk Adjusted Performance | (0.32) | |||
| Mean Deviation | 3.29 | |||
| Semi Deviation | 3.63 | |||
| Downside Deviation | 4.15 | |||
| Coefficient Of Variation | 3055.4 | |||
| Standard Deviation | 5.05 | |||
| Variance | 25.48 | |||
| Information Ratio | 0.0482 | |||
| Jensen Alpha | 0.1137 | |||
| Total Risk Alpha | 0.7345 | |||
| Sortino Ratio | 0.0587 | |||
| Treynor Ratio | (0.33) | |||
| Maximum Drawdown | 31.95 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 6.31 | |||
| Downside Variance | 17.19 | |||
| Semi Variance | 13.2 | |||
| Expected Short fall | (4.46) | |||
| Skewness | 1.78 | |||
| Kurtosis | 7.72 |
Consider Neurosense Therapeutics' intraday indicators
Neurosense Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neurosense Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 22839.37 | |||
| Daily Balance Of Power | 0.3333 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 1.13 | |||
| Day Typical Price | 1.12 | |||
| Period Momentum Indicator | 0.05 |
Neurosense Stock media impact
Far too much social signal, news, headlines, and media speculation about Neurosense Therapeutics that are available to investors today. That information is available publicly through Neurosense media outlets and privately through word of mouth or via Neurosense internal channels. However, regardless of the origin, that massive amount of Neurosense data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neurosense Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurosense Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurosense Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurosense Therapeutics alpha.
Neurosense Therapeutics Corporate Management
| Sharon Vered | Global CMC | Profile | |
| Diana Shtossel | Head Affairs | Profile | |
| Or Eisenberg | Chief Officer | Profile | |
| Nedira SalzmanFrenkel | Global Devel | Profile | |
| Yael Barak | Head Compliance | Profile | |
| Alon BenNoon | CEO CoFounder | Profile | |
| Hagit Binder | VP Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Neurosense Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.